Extended Data Fig. 2: Effect of pegozafermin on serum TGs by subgroup.
From: The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial
Shown are the 95% CIs for median differences. If the percentage of participants within a subgroup was less than 33% of the overall cohort (n < 6), only descriptive analysis is presented. LMT, lipid modifying therapy; PGZ, pegozafermin.
